Three strategic research modules defined in keeping with the national research and innovation strategy and in collaboration with the university of Franche-Comté.

• Biotherapy module

  This module focuses on a topic developed over several years by the CHU in collaboration with the Établissement Français du Sang Bourgogne Franche-Comté (French Blood Establishment of Bourgogne Franche-Comté), recognised with the creation of the Clinical Investigation Centre (CIC-BT) in 2005, now Inserm CIC 1431, and renewed in 2016. Along with UMR - UFC - Inserm 1098, they study the following topics: 

  •  development and assessment of biotherapies in haematology-oncology,
  •  biotherapy and transplantation: cell, tissue and organ transplants,
  •  biotherapies for inflammatory diseases,
  •  human papillomavirus (HPV),
  •  medically assisted procreation (MAP).

• RISQUES module

  RISQUES module: neuro-cardiovascular, infectious and environmental risks

  This module focuses on vulnerabilities and risks and their interactions with social change. In cooperation with UMR - CNRS - UFC 6249 Chrono-environment and EA 3920, 481 and 4267, it includes:

  •  infectious & microbiological risks, including their environmental dimension,
  •  cardioneurovascular risks,
  •  addictions and high-risk behaviours,
  •  ethics and medical progress (with the “IT at the CIC” module), 
  •  oriented toward vulnerability.

• Technological Innovation module

  This module is based on Franche-Comté's unique story, its history in microtechnologies, the existence of a dedicated competitiveness centre, the development of the Femto-ST Institute (UMR CNRS - UFC - ENSEMM - UTBM 6174) and, at the CHU, the current Inserm CIC 1431 Clinical Investigation Centre (CIC-IT), accredited in 2008 and renewed in 2016:

  •  emergence,
  •  microsystems & biological qualifications,
  •  technologies for healthcare in neuropsychiatry,
  •  éthics & medical progress (with the ProMES module).